Effects of hyperfibrinogenemia on vasculature of C57BL/6 mice with and without atherogenic diet

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 23, Issue 1, 2003, Pages 130-135

  Gulledge, Alyssa A ^a   McShea, Cynthia ^a   Schwartz, Todd ^a   Koch, Gary ^a   Lord, Susan T ^a  

^a NONE

Author keywords

Atherogenic diet; Atherosclerosis; Fibrinogen; Hyperfibrinogenemia; Mouse model

Indexed keywords

CHOLESTEROL; FIBRINOGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; ATHEROGENIC DIET; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; FIBRINOGEN BLOOD LEVEL; GENOTYPE; HISTOPATHOLOGY; MORPHOMETRICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 0037235934     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000041037.06509.C2     Document Type: Article

References (16)

1. Meade TW, North WR, Chakrabarti R, Stirling Y, Haines AP, Thompson SG, Brozovie M. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet. 1980;1:1050-1054.
2. Baker IA, Eastham R, Elwood PC, Etherington M Jr, Sweetnam PM. Haemostatic factors associated with ischaemic heart disease in men aged 45 to 64 years: the Speedwell study. Br Heart J. 1982;47:490-494.
3. Wilhelmsen L. Synergistic effects of risk factors. Clin Exp Hypertens. 1990;12:845-863.
4. Wilson PW. Established risk factors and coronary artery disease: the Framingham Study. Am J Hypertens. 1994;7(pt 2):7S-12S.
5. Kannel WB, D'Agostino RB, Belanger AJ. Update on fibrinogen as a cardiovascular risk factor. Ann Epidemiol. 1992;2:457-466.
6. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a metaanalysis and review of the literature. Ann Intern Med. 1993;118:956-963.
7. Smith EB. Fibrinogen, fibrin and the arterial wall. Eur Heart J. 1995;16(suppl A):11-14.
8. Paigen B, Morrow A, Holmes PA, Mitchell D, Williams RA. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis. 1987;68:231-240.
9. Gulledge AA, Rezaee F, Verheijen JH, Lord ST. A novel transgenic mouse model of hyperfibrinogenemia. Thromb Haemost. 2001;86:511-516.
10. Reddick RL, Zhang SH, Maeda N. Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. Arterioscler Thromb. 1994;14:141-147.
11. Paigen B, Morrow A, Brandon C, Mitchell D, Holmes P. Variation in susceptibility to atherosclerosis among inbred strains of mice. Atherosclerosis. 1985;57:65-73.
12. Nishina PM, Verstuyft J, Paigen B. Synthetic low and high fat diets for the study of atherosclerosis in the mouse. J Lipid Res. 1990;31:859-869.
13. Stary HC, Chandler AB, Glagov S, Guyton JR, Insull W Jr, Rosenfeld ME, Schaffer SA, Schwartz CJ, Wagner WD, Wissler RW. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1994;89:2462-2478.
14. Xiao Q, Danton MJ, Witte DP, Kowala MC, Valentine MT, Degen JL. Fibrinogen deficiency is compatible with the development of atherosclerosis in mice. J Clin Invest. 1998;101:1184-1194.
15. McDonagh J. Suppression of plasminogen binding to fibrin by high fibrinogen: a mechanism for how high fibrinogen enhances the risk of thrombosis. Curr Med Lit. 1994;4:2-20.
16. Carr ME Jr, Dent RM, Carr SL. Abnormal fibrin structure and inhibition of fibrinolysis in patients with multiple myeloma. J Lab Clin Med. 1996;128:83-88.